Pricing Log in Create free account
Saturday 17 October 2026 Export EDSA’s income statement to Excel — free account

Edesa Biotech, Inc.

EDSA Healthcare Biotechnology

In the quarter to June 2026, EPS fell 140.0% and free cash flow fell 81.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.57 0.10 −3.75%
Market cap
$36.1M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
3/9
Altman Z
22.29
Beneish M
−4.36
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Edesa Biotech, Inc. (EDSA) Business Profile

Updated before January 2025

Company Overview

Edesa Biotech, Inc. (NASDAQ: EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases. Founded in 2015, the company is headquartered in Markham, Ontario, Canada. Edesa Biotech was established with the mission of addressing unmet medical needs by leveraging advanced scientific research and technology. The company is led by a team of experienced professionals, including Dr. Par Nijhawan, who serves as the Chief Executive Officer. Dr. Nijhawan brings extensive expertise in drug development and commercialization, which has been instrumental in shaping Edesa’s strategic direction.

Core Business Segments

Edesa Biotech operates primarily in the biopharmaceutical sector, with a focus on developing therapies for inflammatory and immune-related conditions. The company’s core business segments include:

1. Dermatology

Edesa is actively developing treatments for dermatological conditions, including chronic skin diseases. One of its flagship products is EB01, a novel topical treatment for allergic contact dermatitis (ACD). EB01 is designed to address the underlying inflammation associated with ACD, offering a potential alternative to corticosteroids and other traditional therapies.

2. Critical Care

The company is also advancing therapies for critical care applications. EB05, another key product in Edesa’s pipeline, is being developed as a treatment for acute respiratory distress syndrome (ARDS), including cases caused by COVID-19. EB05 is an experimental monoclonal antibody therapy that targets the TLR4 signaling pathway, which plays a critical role in the inflammatory response.

3. Immunology

Edesa’s immunology segment focuses on developing therapies that modulate the immune system to treat a range of inflammatory and autoimmune diseases. The company is exploring additional indications for its existing pipeline products and is actively pursuing new therapeutic targets.

Business Model

Edesa Biotech’s business model is centered on the research, development, and commercialization of innovative therapies. The company generates revenue through licensing agreements, partnerships, and potential future product sales. Edesa collaborates with academic institutions, research organizations, and industry partners to accelerate the development of its pipeline products. By focusing on high-value therapeutic areas with significant unmet needs, Edesa aims to create a sustainable business model that delivers both clinical and financial value.

Strategic Direction

Edesa Biotech is committed to advancing its pipeline of innovative therapies and expanding its presence in the biopharmaceutical market. The company’s strategic priorities include:

  • Pipeline Expansion: Edesa plans to continue developing its existing product candidates while exploring new indications and therapeutic targets.
  • Regulatory Approvals: The company is focused on advancing its lead candidates, EB01 and EB05, through clinical trials and obtaining regulatory approvals.
  • Partnerships and Collaborations: Edesa aims to establish strategic partnerships with pharmaceutical companies and research institutions to accelerate product development and commercialization.
  • Sustainability Goals: The company is committed to conducting its operations in an environmentally and socially responsible manner, aligning with global sustainability standards.

Competitive Landscape

Edesa Biotech operates in a highly competitive biopharmaceutical market. Key competitors include:

  • Dermatology: Companies like Dermira (acquired by Eli Lilly) and Arcutis Biotherapeutics are developing treatments for chronic skin conditions.
  • Critical Care: Biopharmaceutical firms such as Regeneron Pharmaceuticals and Gilead Sciences are advancing therapies for ARDS and other critical care indications.
  • Immunology: Competitors in the immunology space include AbbVie, Amgen, and Bristol-Myers Squibb, which have established portfolios of immunomodulatory therapies.

Edesa differentiates itself through its focus on novel mechanisms of action and its commitment to addressing unmet medical needs.

Risk Factors

Edesa Biotech faces several risks that could impact its business operations and financial performance:

  • Clinical Trial Risks: The success of Edesa’s product candidates depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Challenges: Obtaining regulatory approvals for new therapies is a complex and time-consuming process.
  • Market Dependence: The company’s financial performance is heavily reliant on the successful commercialization of its lead candidates.
  • Supply Chain Disruptions: Edesa’s operations could be affected by disruptions in the supply chain for raw materials and manufacturing.
  • Competitive Pressure: The biopharmaceutical market is highly competitive, with numerous established players and emerging startups.

Recent Developments

Edesa Biotech has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Trials: The company recently announced positive interim results from its Phase 2/3 clinical trial of EB05 for ARDS, demonstrating its potential to improve patient outcomes.
  • COVID-19 Research: Edesa has been actively involved in developing therapies for COVID-19-related complications, positioning itself as a key player in the fight against the pandemic.
  • Corporate Partnerships: The company has entered into strategic collaborations with academic institutions and research organizations to accelerate the development of its pipeline products.

Investment Considerations

Investors considering Edesa Biotech should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: Edesa’s focus on novel mechanisms of action and high-value therapeutic areas positions it for long-term growth.
  • Experienced Leadership: The company’s management team has a proven track record in drug development and commercialization.
  • Market Potential: Edesa’s lead candidates target large and underserved markets, offering significant revenue opportunities.

Risks

  • Clinical and Regulatory Uncertainty: The success of Edesa’s product candidates depends on the outcomes of clinical trials and regulatory approvals.
  • Financial Dependence: As a clinical-stage company, Edesa relies on external funding to support its operations and development programs.
  • Competitive Landscape: The biopharmaceutical market is highly competitive, with numerous established players and emerging startups.

Conclusion

Edesa Biotech, Inc. is a promising clinical-stage biopharmaceutical company with a focus on developing innovative therapies for inflammatory and immune-related diseases. With a robust pipeline, experienced leadership, and a commitment to addressing unmet medical needs, Edesa is well-positioned for future growth. However, investors should carefully consider the risks associated with clinical and regulatory uncertainty, as well as the competitive dynamics of the biopharmaceutical market. As Edesa advances its pipeline and pursues strategic partnerships, it has the potential to become a key player in the industry.